α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration

Mosharov, Eugene V., Staal, Roland G. W., Bové, Jordi, Prou, Delphine, Hananiya, Anthonia, Markov, Dmitriy, Poulsen, Nathan, Larsen, Kristin E., Moore, Candace M. H., Troyer, Matthew D., Edwards, Robert H., Przedborski, Serge, Sulzer, David·2006·The Journal of Neuroscience
DOI 10.1523/jneurosci.0519-06.2006

Cited by (164)

Items 101–164 of 164

  1. Lewy Body Disorders
    K. A. Jellinger · 2007 · Springer eBooks
  2. Neuroscience and heart-brain medicine: The year in review
    David S. Goldstein · 2010 · Cleveland Clinic Journal of Medicine
  3. Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells
    Sa Suk Kim, Kyung Rok Moon, Hyun Jin Choi · 2011 · Archives of Pharmacal Research
  4. The “Sick-but-not-Dead” Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases
    David S. Goldstein · 2020 · Seminars in Neurology
  5. Literature-Related Discovery (LRD)
    Ronald Neil Kostoff, Joel A. Block, Jeffrey L. Solka, Michael Brandon Briggs, Robert L. Rushenberg, Jesse A. Stump, Dustin Johnson, Terence J. Lyons, Jeffrey R. Wyatt · 2007 · Defense Technical Information Center (DTIC)
  6. Visualization of early oligomeric α‐synuclein pathology and its impact on the dopaminergic system in the (Thy‐1)‐h[A30P]α‐syn transgenic mouse model
    Anish Behere, Per‐Ove Thörnqvist, Svante Winberg, Martin Ingelsson, Joakim J. E. Bergström, Sara Ekmark‐Lewén · 2021 · Journal of Neuroscience Research
  7. A pragmatic approach to biochemical systems theory applied to an α-synuclein-based model of Parkinson's disease
    Matthew B. Sass, Alyson N. Lorenz, Robert L. Green, Randolph A. Coleman · 2008 · Journal of Neuroscience Methods
  8. Chronic Opioid Treatment Arrests Neurodevelopment and Alters Synaptic Activity in Human Midbrain Organoids
    Hye Sung Kim, Yang Xiao, Xuejing Chen, Siyu He, Jongwon Im, Moshe J. Willner, Michael O. Finlayson, Cong Xu, Huixiang Zhu, Se Joon Choi et al. · 2024 · Advanced Science
  9. Perivascular nerve fiber α-synuclein regulates contractility of mouse aorta: A link to autonomic dysfunction in Parkinson's disease
    Vannina G. Marrachelli, Francisco J. Miranda, José A. Alabadí, Miguel Milán, Marifé Cano‐Jaimez, Martina Kirstein, Enrique Alborch, Isabel Fariñas, Francisco Pérez‐Sánchez · 2010 · Neurochemistry International
  10. Mitochondrial dysfunction and oxidative damage in the molecular pathology of Parkinson’s disease
    Maria I. Shadrina, Petr A. Slominsky · 2008 · Molecular Biology
  11. Systematic literature review on Parkinson's disease and Childhood Leukaemia and mode of actions for pesticides
    Judy Choi, Alexandra Anne Polcher, Anke Joas · 2016 · EFSA Supporting Publications
  12. PKC θ activity maintains normal quantal size in chromaffin cells
    Roland G. W. Staal, Anthonia Hananiya, David L. Sulzer · 2008 · Journal of Neurochemistry
  13. Exploring the Interaction of Human α-Synuclein with Polyethylene Nanoplastics: Insights from Computational Modeling and Experimental Corroboration
    Neha Tripathi, Florent Saudrais, Mona Rysak, Laura Pieri, Serge Pin, Guido Roma, Jean‐Philippe Renault, Yves Boulard · 2024 · Biomacromolecules
  14. Polymorphism in theVesicular Monoamine Transporter 2Gene Decreases the Risk of Parkinson’s Disease in Han Chinese Men
    Xinglong Yang, Pingrong Xu, Quanzhen Zhao, Ran An, Hua Jia, Zhuolin Liu, Yanming Xu · 2015 · Parkinson s Disease
  15. The Low Affinity Dopamine Binding Site on Tyrosine Hydroxylase: The Role of the N-Terminus and In Situ Regulation of Enzyme Activity
    Sarah L. Gordon, Julianne K. Webb, Jacqueline Shehadeh, Peter Robert Dunkley, Phillip W. Dickson · 2009 · Neurochemical Research
  16. Oxidative Stress in Parkinson`s Disease
    Avi L. Friedlich, Mark A. Smith, Xiongwei Zhu, Atsushi Takeda, Akihiko Nunomura, Paula Isabel Moreira, George L. Perry · 2009 · The Open Pathology Journal
  17. Neurotoxicology of dopamine: Victim or assailant?
    Meghan L. Bucher, Jocelyn Dicent, Gary W. Miller · 2024 · NeuroToxicology
  18. An ultra-sensitive platinized nanocavity electrode for analysis of cytosolic catecholamines in one living cell
    Yuanyuan Ma, Yanyu Ma, Kang Liu, Dengchao Wang, Rujia Liu, Quanchi Chen, Dechen Jiang, Rongrong Pan · 2023 · Talanta
  19. Dopamin, oxidativer Stress und Protein‐Chinonmodifikationen bei Parkinson und anderen neurodegenerativen Erkrankungen
    Enrico Monzani, Stefania Nicolis, Simone Dell’Acqua, Andrea Capucciati, Chiara Bacchella, Fabio Andrea Zucca, Eugene V. Mosharov, David Sulzer, Luigi Zecca, Luigi Casella · 2018 · Angewandte Chemie
  20. Induction of neuronal damage in guinea pig brain by intratracheal infusion of 2‐chloroethyl ethyl sulfide, a mustard gas analog
    Jessica Gadsden‐Gray, Shyamali Mukherjee, Olugbemiga Ogunkua, Salil K. Das · 2011 · Journal of Biochemical and Molecular Toxicology
  21. Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging
    Ana Pérez‐Villalba, Ma Salomé Sirerol-Piquer, Raúl Soriano‐Cantón, Virginia Folgado-Marco, Azucena Pérez‐Cañamás, Martina Kirstein, Isabel Fariñas, Francisco Pérez‐Sánchez · 2024 · Scientific Reports
  22. Etiology and pathogenesis of Parkinson disease
    Joseph J. Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn, Jennifer G. Goldman · 2021 · Elsevier eBooks
  23. Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase
    Marta González-Sepúlveda, Muhammad Yusof Omar, Sally Hamdon, Guofen Ma, Santi Rosell-Vilar, Noora Raivio, Doaa Abass, Anna Martínez-Rivas, Miquel Vila, Jesús Giraldo et al. · 2022 · Neuropharmacology
  24. Oxidative Stress in Parkinson’s Disease: Role in Neurodegeneration and Targets for Therapeutics
    Rebecca Banerjee, Navneet Ammal Kaidery, Bobby Thomas · 2015 · ACS symposium series
  25. Current concepts on the etiology and pathogenesis of Parkinson disease
    Stanley Fahn, Joseph J. Jankovic, Mark Hallett · 2011 · Elsevier eBooks
  26. Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility?
    Jonathan Sackner‐Bernstein · 2024 · Journal of Neurology
  27. Towards Small Molecules as Therapies for Alzheimer’s Disease and Other Neurodegenerative Disorders
    Omar Aziz, Roland W. Bürli, David F. Fischer, Julie A. Frearson, Michael D. Wall · 2014 · Elsevier eBooks
  28. Interaction Between α-Synuclein and DJ-1 in Parkinson’s Disease
    Pouya Sobhifar, David R. Brown · 2025 · Brain Sciences
  29. Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases
    David S. Goldstein · 2026 · Journal of Clinical Neurology
  30. Predictive modeling of putamen dopamine in Parkinson’s disease: relevance to prognosis, treatment, and prevention
    David S. Goldstein · 2026 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
  31. Dopamine neurotransmission in Parkinson's disease
    Kaitlyn M.L. Cramb, Humaira Noor, Richard Wade-Martins, Stephanie J. Cragg · 2025 · Handbook of behavioral neuroscience
  32. Dopamine Homeostasis and Role of VMAT2 in Neurodegeneration
    Eugene V. Mosharov · 2022 · Springer eBooks
  33. Regulation of DA Homeostasis and Role of VMAT2 in DA-Induced Neurodegeneration
    Eugene V. Mosharov · 2014 · Springer eBooks
  34. Dopamine Homeostasis and Role of VMAT2 in Neurodegeneration
    Eugene V. Mosharov · 2021 · Springer eBooks
  35. Neuroprotective and Neurotoxic Properties of α-Synuclein in Cell Culture Models of Dopaminergic Degeneration
    Faneng Sun, Vellareddy Anantharam, Huajun Jin, Danhui Zhang, Arthi Kanthasamy, Anumantha G. Kanthasamy · 2008 · Elsevier eBooks
  36. Drosophila as a Neurotoxicological Model
    Hakeem O. Lawal, David E. Krantz · 2018 · Methods in pharmacology and toxicology
  37. Structural and Functional Insights into α‐Synuclein–Lipid Interactions
    Martin Thomas Stöckl, Bart D. van Rooijen, Mireille M. A. E. Claessens, Vinod Subramaniam · 2011 · Wiley eBooks
  38. Neuroprotective effects of amantadine–flavonoid conjugates
    Petrus Michiel Fourie · 2011
  39. Dopamine‐Derived Neurotoxicity and Parkinson's Disease
    José Luis Labandeira-García · 2009 · Wiley eBooks
  40. Alpha-synuclein and the multiple hit hypothesis of Parkinson's disease
    Li Feng · 2012 · DigitalGeorgetown (Georgetown University Library)
  41. CyDAP–A fluorescent probe for cytosolic dopamine detection
    Jing‐Yi Jeng, Sun Lee, Jia‐Chi Wang, Cheng-Yuan Lin, Chih-Ping Hung, Li‐An Chu, Hui-Yun Chang, Ann‐Shyn Chiang, Tzu‐Kang Sang · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Role of alpha-synuclein in the regulation of dopamine neurotransmission in the striatum
    Heramb Chadchankar · 2013 · UEF eRepo (University of Eastern Finland)
  43. THE ROLE OF DOPAMINE OXIDATION IN DOPAMINE-INDUCED TOXICITY, INITIATION OF ENDOPLASMIC RETICULUM STRESS, AND POTENTIATION OF ROTENONE-INDUCED TOXICITY IN DIFFERENTIATED PC12 CELLS
    April A. Dukes · 2007 · D-Scholarship@Pitt (University of Pittsburgh)
  44. Investigation of the process of SNARE mediated synaptic vesicle exocytosis
    Ying Lai · 2013 · Iowa State University Digital Repository (Iowa State University)
  45. Targeting α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy
    Arianna Bellucci, PierFranco Spano · 2011 · InTech eBooks
  46. Mechanisms of aluminium neurotoxicity in oxidative stress-induced degenerative processes in relation to parkinson's disease
    Sofía Sánchez Iglesias · 2011 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  47. Probing yeast for insights into neurodegenerative disease: ORFeome-wide screens for genetic modifiers of -synuclein cytotoxicity
    Richard A. Manfready · 2010 · Biotechnology and Molecular Biology Reviews
  48. Convergence of Multiple Hits that Could Underlie Parkinson‘s Disease
    Eugene V. Mosharov, David L. Sulzer · 2009 · Future Neurology
  49. Effects of Mutant Alpha-Synuclein In the Activation of Retrograde Fast Axonal Transport
    Sun Kyong Lee (7971380) · 2013 · Figshare
  50. The role of alpha-synuclein phosphorylation in synucleinopathies
    Elisa Basso · 2014 · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
  51. Mutation in VMAT2 Causing a Pediatric Neurotransmitter Disease
    Jennifer J. Rilstone · 2015 · TSpace (University of Toronto)
  52. Studying Oxidative Stress: Real-Time Detection of Hydrogen Peroxide and Dopamine Dynamics in the Brain.
    Leslie R. Wilson · 2018 · NCSU Libraries Repository (North Carolina State University Libraries)
  53. a Circulating cell free mitochondrial DNA copy number variation in neurodegenerative disease
    Hannah Lowes · 2018
  54. Trafficking and Activity Dependent Function of Vesicular Transporters
    Lesley A. Colgan · 2009 · D-Scholarship@Pitt (University of Pittsburgh)
  55. The role of RNA in synapse physiology and neurodegeneration in models of Parkinson´s disease
    Maria Xylaki · 2021
  56. Patch Amperometry and Intracellular Patch Electrochemistry
    Eugene V. Mosharov, Manfred Lindau · 2022 · Methods in molecular biology
  57. Preclinical Validation of FTY720 and FTY720-Mitoxy in Mouse Models of Parkinsons Disease and Multiple System Atrophy (MSA): Evidence for Treating Lewy Body Disease Synucleinopathies Including MSA
    Guadalupe Vidal-Martínez, Haiyan Lou, Ruth G. Perez · 2024 · IntechOpen eBooks
  58. Combining dopamine and glucose sensings on paper devices for the metabolic study of neurosecretion
    Rémi F. Dutheil, Dabeaurard Tho, Iman Pitroipa, Raphaël Trouillon · 2025 · Biosensors and Bioelectronics X
  59. Dopamine release from Parkinson’s patient-derived neurons is disrupted due to impaired synaptic vesicle loading
    Kaitlyn M. L. Cramb, Humaira Noor, Iona Thomas-Wright, Maria Claudia Caiazza, Sándor Szunyogh, Ira Milošević, Dayne A. Beccano-Kelly, Stephanie Jane Cragg, Richard Wade‐Martins · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  60. Rôles de FOXO3 dans la réponse cellulaire au stress et la neurodégénérescence au cours de la maladie Parkinson
    Baptiste Texier · 2024 · theses.fr (ABES)
  61. Phytochemical engineered quantum dots as potential therapy to counter alpha synuclein aggregation in Parkinson's disease
    Priya Shashwat, Vishnu Kirthi Arivarasan, Manickam Selvaraj, Arun Karnwal, Joydeep Dutta · 2026 · Neurochemistry International
  62. BindingDB Entry 50016957: Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
    BindingDB · 2023 · UC San Diego
  63. Step-specific investigation of SNARE-mediated membrane fusion
    Sunae Kim · 2013
  64. Unraveling the mechanisms of alpha-synuclein aggregation and toxicity
    Nicoletta Plotegher · 2013 · Padua@research (University of Padova)